Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST

Myriad’s True Value

by

Some interesting points raised in a NY Times editorial yesterday regarding Myriad’s true underlying value being in its database of mutations. In a paper referenced by the editorial the authors describe Myriad’s database of BRCA1/2 mutations and the value of the company’s ability to understand the phenotypic significance of variations that remain unknown to everyone else (making their algorithms far more accurate).

The next controversy in genetic testing: clinical data as trade secrets?